Evidence map›Paper›PMID 40554537›Full record

ArticlePloS one2025

Genetic markers for knee osteoarthritis presence are not associated with disease progression - data from the IMI-APPROACH cohort.

Mieke L M Bentvelzen, Paco M J Welsing, Philippe Moingeon, Simon C Mastbergen, Margreet Kloppenburg, Francisco J Blanco, Ida K Haugen, Francis Berenbaum, Hae-Won Uh, Mylène P Jansen and 1 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mieke L M BentvelzenDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0009-0003-5054-1569
Paco M J WelsingDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Philippe MoingeonUniversity Paris Saclay, UFR Pharmacy, Saclay France.
Simon C MastbergenDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Margreet KloppenburgRheumatology, Leids Universitair Medisch Centrum, Leiden, Zuid-Holland, The Netherlands.
Francisco J BlancoGrupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS. Centro de Investigación CICA, Departamento de Fisioterapia y Medicina, Universidad de A Coruña, A Coruña, Spain.ORCID 0000-0001-9821-7635
Ida K HaugenCenter for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
Francis BerenbaumDepartment of Rheumatology, Sorbonne University, INSERM, AP-HP Saint-Antoine hospital, Paris, France.
Hae-Won UhDepartment of Data Science and Biostatistics, div. Julius Centrum, University Medical Center Utrecht, The Netherlands.
Mylène P JansenDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0003-1929-6350
Said El BouhaddaniDepartment of Data Science and Biostatistics, div. Julius Centrum, University Medical Center Utrecht, The Netherlands.ORCID 0000-0002-2279-4337

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveKnee osteoarthritis (OA) is a heterogeneous disease with different endotypes and phenotypes, resulting in patients' varying clinical and structural progression. Several genomic markers have been associated with knee OA presence. This study aimed to find new associations of these genetic markers with knee OA progression and to investigate the risk of knee OA progression using a polygenic risk score (PRS).

methodsData from knee OA patients (n = 297) from the IMI-APPROACH cohort with detailed measurements on disease progression were used. Knee OA progression definitions were based on the decrease in minimum joint space width in mm (minJSW; primary outcome), increase in pain on the Knee injury and Osteoarthritis Outcome Score (KOOS), and presence of radiographic OA (based on the Kellgren-Lawrence score) over 24 months. 30 previously reported single nucleotide polymorphisms (SNPs) associated with presence of OA irrespective of affected joints or knee OA specifically were investigated. We performed a SNP based genome-wide association analysis using the disease progression definitions. Furthermore, a PRS was created using the 30 presence SNPs to predict knee OA progression.

resultsExisting genetic markers for knee OA presence were not found to be associated with knee OA progression. The PRS of the SNPs for knee OA presence did also not show significant predictive value for knee OA progression. Unexpectedly, nineteen different variants were associated significantly (P < 5 × 10-8) with minJSW decrease. Ten SNPs are located near protein coding genes PLCL2, CDYL2, and NTNG1, and several SNPs are located in or near long non-coding RNAs (lncRNA).

conclusionsThe 30 OA risk SNPs individually and combined in a PRS are not associated with progression of knee OA in the IMI-APPROACH cohort. 19 different SNPs were associated with minJSW decrease. We demonstrated how to employ multiple bioinformatics tools to, despite a limited dataset, still prioritise potential biomarkers for associations to knee OA progression.

Indexed as

Osteoarthritis, KneeAgedCohort StudiesDisease ProgressionFemaleGenetic MarkersGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleMiddle AgedPolymorphism, Single NucleotideGenetic Markers

Identifiers

PMID40554537
PMCPMC12186935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.